JMP Securities analyst David Turkaly lowered the firm’s price target on Integra LifeSciences to $60 from $65 and keeps an Outperform rating on the shares. Quarterly results were better than feared due mainly to strength in CSS, particularly in Instruments, while initial Q3 guidance was slightly below Street expectations, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IART:
- Integra LifeSciences sees Q3 adjusted EPS 76c-80c, consensus 84c
- Integra LifeSciences lowers FY23 EPS view to $3.10-$3.18 from $3.43-$3.51
- Integra LifeSciences reports Q2 adjusted EPS 71c, consensus 57c
- Integra LifeSciences Reports Second Quarter 2023 Financial Results
- Integra Lifesciences (IART) Q2 Earnings Cheat Sheet